



ICR-AMI-011

Cardiology · critical care
Updated 20 Jun 2026

CRITICAL CARE ORDER SET

Acute Myocardial Infarction

Initial ED / inpatient management of adult AMI. For suspected STEMI, activate the cath lab immediately — time is muscle. Give aspirin, load a P2Y₁₂ inhibitor, anticoagulate, and start guideline-directed medical therapy while pursuing reperfusion. Adapt every dose to your institutional protocol, formulary, cath-lab access, and the patient in front of you.

PATIENT -----	MRN -----	WEIGHT (KG) -----	TYPE — STEMI / NSTEMI -----
ALLERGIES -----	SYMPTOM ONSET TIME -----	ORDERING CLINICIAN -----	CODE STATUS -----

01 Admission & level of care

TIME IS MUSCLE For suspected STEMI (or new LBBB with strong suspicion), **activate the cath lab now** — door-to-balloon goal ≤ 90 minutes. Do not delay reperfusion for ancillary testing.

ADMIT TO

- ☐ **Cardiac ICU / high-acuity stepdown** — STEMI, high-risk NSTEMI, hemodynamic instability
- OR
- ☐ **Telemetry unit** — lower-risk NSTEMI / unstable angina
- ☐ Code status: [] Full code [] Other: _____

NOTIFY SERVICES

- ☐ **Interventional cardiology STAT** — suspected STEMI or high-risk NSTEMI

- ☐ Cardiology consult
- ☐ ICU / CCU team if not primary

02 Monitoring & nursing

- ☐ Continuous cardiac monitoring (telemetry)
- ☐ Vital signs: **q15 min × 1 h**, then **q30 min × 2 h**, then **q4 h** (or per ICU protocol)
- ☐ Continuous pulse oximetry
- ☐ Strict intake & output; daily weight
- ☐ Bed rest initially; assist with bathroom / commode
- ☐ Falls precautions

03 Diagnostics

IMMEDIATE — STAT

- ☐ **12-lead ECG now** (if not already obtained)
- ☐ Repeat 12-lead ECG **q15–30 min** if ongoing chest pain or deterioration
- ☐ High-sensitivity troponin (or institutional biomarker)
- ☐ CBC with differential
- ☐ CMP (electrolytes, BUN, Cr, liver enzymes)
- ☐ Coagulation panel — PT / INR, aPTT
- ☐ Lipid panel (fasting if feasible; do not delay treatment)
- ☐ HbA1c
- ☐ Type & screen (or cross if high bleeding risk / procedure)
- ☐ Magnesium, phosphorus
- ☐ Serum β -hCG (childbearing potential)
- ☐ Chest x-ray (portable preferred)

WITHIN 24 HOURS

- ☐ Transthoracic echocardiogram — LV function, wall motion, complications, valvular disease
- ☐ Repeat troponin per protocol (e.g., at 3 and 6 h from presentation)

04 Oxygen & symptom control

OXYGEN

- ☐ Target SpO₂ ≥ **90–92%** (≥ 94% if no COPD)
- ☐ Nasal cannula **2–4 L/min only** if SpO₂ < 90–92% or respiratory distress

PAIN / ANXIETY

- ☐ **Nitroglycerin SL 0.4 mg q5 min × up to 3 doses** PRN chest pain

HOLD NITRO IF SBP < 90 mmHg or ≥ 30 mmHg drop from baseline · HR < 50 or > 100 with hypotension · suspected RV infarct · recent PDE5 inhibitor (sildenafil / vardenafil within 24 h, tadalafil within 48 h).

- ☐ Morphine **1–2 mg IV q5–10 min** PRN severe pain not relieved by nitro — use cautiously (hypotension, bradycardia, respiratory depression)
- ☐ Consider low-dose IV / PO benzodiazepine PRN severe anxiety if hemodynamically stable

05 Antiplatelet therapy

ASPIRIN — IF NO TRUE ALLERGY / ACTIVE MAJOR BLEEDING

- ☐ **Aspirin 325 mg PO (chewed)** once now
- ☐ Then **aspirin 81 mg PO daily**

P2Y₁₂ INHIBITOR — PRIMARY PCI / EARLY INVASIVE (CHOOSE ONE)

- ☐ **Ticagrelor** 180 mg PO load, then 90 mg PO BID
- OR
- ☐ **Clopidogrel** 600 mg PO load (300 mg if older / frail / bleeding risk), then 75 mg PO daily
- OR
- ☐ **Prasugrel** 60 mg PO load, then 10 mg PO daily

Prasugrel contraindications: prior stroke / TIA · age ≥ 75 (relative) · weight < 60 kg (consider 5 mg daily)

P2Y₁₂ INHIBITOR — FIBRINOLYSIS STRATEGY (STEMI WITHOUT TIMELY PCI)

- ☐ Age ≤ 75: **clopidogrel 300 mg PO load**, then 75 mg PO daily

- ☐ Age > 75: clopidogrel 75 mg PO daily without loading

06 Anticoagulation

Primary PCI strategy

- ☐ UFH IV bolus 60–70 units/kg (max 4,000–5,000), then 12–15 units/kg/h (max ~1,000/h), titrate to aPTT / anti-Xa or cath-lab protocol
 - ☐ Check baseline aPTT, platelets; repeat per protocol
- ALTERNATIVE
- ☐ Bivalirudin regimen for PCI (per cardiology protocol)
 - ☐ GP IIb/IIIa inhibitor (eptifibatide / tirofiban / abciximab) — only if directed by interventional cardiology (large thrombus, bail-out)

Conservative NSTEMI / UA (no immediate PCI)

- ☐ UFH infusion as above
- OR
- ☐ Enoxaparin 1 mg/kg SC q12h (q24h if CrCl < 30 mL/min); adjust for obesity / renal function

Fibrinolytic strategy (STEMI)

- ☐ Follow local protocol — usually UFH infusion or enoxaparin with weight / age / renal adjustments

07 Reperfusion / invasive strategy

STEMI (OR NEW LBBB WITH STRONG SUSPICION)

- ☐ Activate cath lab for primary PCI — door-to-balloon goal ≤ 90 min
- ☐ If PCI unavailable within guideline times and no contraindications: fibrinolytic therapy per protocol (e.g., tenecteplase weight-based IV bolus, or alteplase regimen)

BEFORE LYSIS Screen for absolute / relative contraindications: prior intracranial hemorrhage, recent stroke, intracranial neoplasm / AVM, active bleeding, suspected aortic dissection, significant head trauma or recent major surgery.

- ☐ Post-lysis transfer for rescue or routine PCI per protocol

NSTEMI / HIGH-RISK UNSTABLE ANGINA

- ☐ **Early invasive strategy** — diagnostic ± interventional coronary angiography within 24 h (sooner if instability, refractory angina, arrhythmias, or high-risk features)
- ☐ Conservative strategy only if low risk or major contraindications to angiography — ensure close monitoring

08

Anti-ischemic & guideline-directed medical therapy

BETA-BLOCKER — IF NO CONTRAINDICATIONS

CAUTION Start within 24 h if hemodynamically stable. **Avoid** in acute heart failure, cardiogenic shock, bradycardia, or high-degree AV block.

- ☐ **Metoprolol tartrate 25–50 mg PO q6–12h**; titrate to HR 50–60 and BP tolerance
- ☐ If IV considered: metoprolol 5 mg IV q5 min × 3, then oral (caution in borderline hemodynamics / older patients)

ACE INHIBITOR / ARB

- ☐ Start within 24 h if LV systolic dysfunction ($EF \leq 40\%$), anterior MI, diabetes, or CKD — and not hypotensive / in shock
- ☐ **Lisinopril 2.5–5 mg PO daily**, titrate as tolerated
- ☐ If ACEI-intolerant (cough, angioedema): losartan 25–50 mg PO daily or valsartan 40 mg PO BID

HIGH-INTENSITY STATIN

- ☐ **Atorvastatin 80 mg PO once now**, then 80 mg PO nightly
- ☐ If intolerant: rosuvastatin 20–40 mg nightly or moderate-intensity alternative

NITRATES (BEYOND SL) & MRA

- ☐ For persistent angina or hypertension without hypotension: **nitroglycerin IV infusion** (start 5–10 mcg/min, titrate) — hold in RV infarct, hypotension, or PDE5 use
- ☐ After stabilization, if $EF \leq 40\%$ with diabetes or HF (K^+ and creatinine appropriate): MRA — spironolactone 12.5–25 mg PO daily

09 Glycemic management

- ☐ Target blood glucose **140–180 mg/dL** (avoid tight control / hypoglycemia)
- ☐ POC glucose on arrival, then before meals and at bedtime (or **q6 h** if NPO)
- ☐ Basal/bolus insulin or IV insulin per ICU protocol for persistent hyperglycemia
- ☐ Hold most oral hypoglycemics acutely (metformin with renal dysfunction / hypotension / contrast; SGLT2 inhibitors, etc.)

10 Supportive & preventive orders

- ☐ **NPO** initially if urgent PCI anticipated; liberalize diet after procedure / stabilization

DVT PROPHYLAXIS — IF NOT FULLY ANTICOAGULATED / HIGH BLEED RISK

- ☐ Enoxaparin 40 mg SC daily, or UFH 5,000 units SC q8–12h per protocol

GI PROPHYLAXIS & BOWEL REGIMEN

- ☐ PPI if high GI-bleed risk (age, prior ulcer, dual antiplatelet, anticoagulant use)
- ☐ Docusate ± senna PRN constipation, particularly if opioids given

VACCINATION REVIEW

- ☐ Consider influenza and pneumococcal vaccines before discharge per guidelines

11 Serial assessment & complication surveillance

- ☐ Serial physical exams for signs of HF, shock, new murmurs, or mechanical complications
- ☐ Daily ECG if indicated; immediate ECG and biomarkers for recurrent chest pain
- ☐ Telemetry for arrhythmia detection (VT/VF, AF, AV block)
- ☐ Titrate therapies based on BP, HR, renal function, and symptoms

12 Discharge planning — start during hospitalization

SECONDARY PREVENTION

☐ Aspirin 81 mg PO daily indefinitely
(unless contraindicated)

☐ P2Y₁₂ inhibitor for 12 months post-MI
(shorter / longer per bleeding risk &
cardiology)

☐ High-intensity statin (atorvastatin 80 mg
daily)

☐ Beta-blocker

☐ ACEI / ARB ± MRA when indicated

LIFESTYLE / REHAB

☐ Cardiac rehabilitation referral

☐ Smoking cessation counseling +
pharmacotherapy PRN

☐ Dietitian consult (Mediterranean-style /
cardioprotective diet)

☐ Physical therapy / exercise
recommendations as appropriate

FOLLOW-UP

☐ Cardiology follow-up within 1–2 weeks of discharge

☐ PCP follow-up within 2–4 weeks

EDUCATIONAL USE ONLY

Not a substitute for clinical judgement. Verify doses, allergies, renal function, and contraindications. Adapt all agents and thresholds to your institutional protocols, formulary, cath-lab access, and the individual patient.

Spreading knowledge
Improving outcomes